Vertex Pharmaceuticals Incorporated vs DENTSPLY SIRONA Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B), while DENTSPLY SIRONA Inc trades at $13.56 (market cap $2.70B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 45.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | XRAY | |
|---|---|---|
Market Cap | $121.95B | $2.70B |
Sector | Health | Health |
52-Week High | $529.59 | $16.85 |
52-Week Low | $366.54 | $9.64 |
Enterprise Value | $116.69B | $4.84B |
Dividend Yield | — | 5.04% |
Trailing returns across standard periods
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →